|本期目录/Table of Contents|

[1]黄昂,梁庆升,孙颖,等.慢性药物性肝损伤的诊治研究进展[J].传染病信息,2018,02:105-107.
 HUANG Ang,LIANG Qing-sheng,SUN Ying,et al.Research progress in the diagnosis and treatment of chronic drug-induced liver injury[J].Infectious Disease Information,2018,02:105-107.
点击复制

慢性药物性肝损伤的诊治研究进展(PDF)

《传染病信息》[ISSN:1007-8134/CN:11-3886/R]

期数:
2018年02期
页码:
105-107
栏目:
导向与述评
出版日期:
2018-03-20

文章信息/Info

Title:
Research progress in the diagnosis and treatment of chronic drug-induced liver injury
作者:
黄昂梁庆升孙颖邹正升
100039 北京,解放军第三〇二医院非感染性肝病诊 疗与研究中心(黄昂、梁庆升、孙颖、邹正升) 前两位作者对本文有同等贡献,均为第一作者
Author(s):
HUANG Ang LIANG Qing-sheng SUN Ying ZOU Zheng-sheng*
Diagnostic and Treatment Center of Non-infectious Liver Diseases, 302 Military Hospital of China, Beijing 100039, China HUANG Ang and LIANG Qing-sheng are the first authors who contributed equally to the article
关键词:
慢性药物性肝损伤诊断治疗进展
Keywords:
chronic drug-induced liver injury diagnosis treatment progress
分类号:
R575
DOI:
10.3969/j.issn.1007-8134.2018.02.003
文献标识码:
A
摘要:
慢性药物性肝损伤(drug-induced liver injury, DILI)是药物不良反应中较为严重的一种疾病。随着新药的不断 研发及临床应用,以及中药和食物补充剂的应用,慢性DILI 的发生率不断增高。因此,充分了解其诊断及治疗对慢性DILI 患者非常重要。本文对慢性DILI 的最新研究进展作一概述,以期更加全面地了解该疾病。
Abstract:
Chronic drug-induced liver injury (DILI) is a serious disease among adverse drug reactions. With continuous development and clinical application of new drugs, as well as the application of herbal and dietary supplements, the incidence of chronic DILI shows a steady increase. Therefore, it is very important for DILI patients to fully understand its diagnosis and treatment. This study aims to comprehend this disease thoroughly through reviewing the latest research findings concerning chronic DILI.

参考文献/References

[1] Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for druginduced liver injury[J]. Hepatology, 2013, 58(1):388-396.
[2] Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic druginduced liver injury[J]. Am J Gastroenterol, 2014, 109(7):950- 966; quiz 967.
[3] Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study[J]. Hepatology, 2002, 36(2):451-455.
[4] Bjornsson ES, Bergmann OM, Bjornsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland[J]. Gastroenterology, 2013, 144(7):1419-1425, 1425.e1-e3.
[5] Chang B, Li B, Huang A, et al. Changes of four common noninfectious liver diseases for the hospitalized patients in Beijing 302 hospital from 2002 to 2013[J]. Alcohol, 2016, 54:61-65.
[6] Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry[J]. Hepatology, 2006, 44(6):1581-1588.
[7] Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury[J]. Clin Pharmacol Ther, 2011, 89(6):806-815.
[8] Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the dilin prospective study[J]. Gastroenterology, 2015, 148(7):1340- 1352.
[9] Fontana RJ, Seeff LB, Andrade RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop[J]. Hepatology, 2010, 52(2):730-742.
[10] Kleiner DE, Chalasani NP, Lee WM, et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations[J]. Hepatology, 2014, 59(2):661-670.
[11] Fontana RJ, Hayashi PH, Gu J, et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset[J]. Gastroenterology, 2014, 147(1): 96-108.
[12] Fontana RJ, Hayashi PH, Barnhart H, et al. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury[J]. Am J Gastroenterol, 2015, 110(10):1450-1459.
[13] Medina-Caliz I, Robles-Diaz M, Garcia-Munoz B, et al. Definition and risk factors for chronicity following acute idiosyncratic druginduced liver injury[J]. J Hepatol, 2016, 65(3):532-542.
[14] Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States[J]. Gastroenterology, 2008, 135(6):1924-1934, 1934.e1-e4.
[15] Daly AK, Day CP. Genetic association studies in drug-induced liver injury[J]. Drug Metab Rev, 2012, 44(1):116-126.
[16] Alfirevic A, Gonzalez-Galarza F, Bell C, et al. In silico analysis of HLA associations with drug-induced liver injury: use of a HLAgenotyped DNA archive from healthy volunteers[J]. Genome Med, 2012, 4(6):51.
[17] Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-induced liver injury network (DILIN) prospective study: rationale, design and conduct[J]. Drug Saf, 2009, 32(1):55-68.
[18] Sebode M, Schulz L, Lohse AW. "Autoimmune(-Like)" drug and herb induced liver injury: new insights into molecular pathogenesis [J]. Int J Mol Sci, 2017, 18(9). pii:E1954.
[19] Weiler-Normann C, Schramm C. Drug induced liver injury and its relationship to autoimmune hepatitis[J]. J Hepatol, 2011, 55(4):747-749.
[20] Bonkovsky HL, Kleiner DE, Gu J, et al. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements[J]. Hepatology, 2017, 65(4):1267-1277.

备注/Memo

备注/Memo:
[基金项目] 国家自然科学基金(81600453);北京市科技新星计 划(Z171100001117114);军队医学科技青年培育计划(15QNP084)
[通信作者] 邹正升,E-mail: zszou302@163.com
更新日期/Last Update: 2018-03-20